CAR-T

This page shows the latest CAR-T news and features for those working in and with pharma, biotech and healthcare.

Novartis raises 2019 guidance as new products gather speed

Novartis raises 2019 guidance as new products gather speed

from new prostate cancer therapy Lutathera, Kisqali (ribociclib) for breast cancer and CAR-T Kymriah (tisagenlecleucel). ... It wasn’t all positive news for the company of course. Kymriah’s $58m contribution in the quarter is only slightly up on the

Latest news

More from news
Approximately 36 fully matching, plus 134 partially matching documents found.

Latest Intelligence

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    We won’t compete directly with big vaccine companies, but may partner with them to support late phase product development and commercialisation. ... This is hard to know. The value of T cell approaches, especially CD8 T cells, has been shown by the

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... This is demonstrated in Gilead securing two truly groundbreaking partnerships

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    This is informed by the experience of CAR-T cell therapies, where Novartis’ Kymriah – the first ever CAR-T approved in 2017 – looks set to remain a loss-leader for many ... Its most important pipeline candidate, however, is the multiple myeloma

  • “Brexit has been a catalyst for UK clinical research... it’s turbocharged change” “Brexit has been a catalyst for UK clinical research... it’s turbocharged change”

    He said it remains a frustration that international perceptions of UK clinical research haven’t kept pace with that change in performance on the ground. ... can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah

  • Cell and gene therapy Cell and gene therapy

    In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... Manufacturing of CAR-T cell therapies is a highly sophisticated,

More from intelligence
Approximately 0 fully matching, plus 48 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 8 partially matching documents found.